Administrative Core

项目概要（APOE U19核心A：行政核心） 行政核心将通过提供行政、财政和科学监督来领导这个U19项目。 促进所有核心和项目的协同作用，以解决ApoE级联假说。核心A将服务于 几个功能，以促进科学的目标和严谨性，这U19。它还将服务于更广泛的 科学界通过门户网站共享知识、资源和数据集， 通过年度ApoE研讨会进行合作。核心A将与NIA倡议充分合作， 敬业的领导团队和具有相关经验的行政人员。作为U19的联合PI 项目和核心A的共同负责人，马约诊所杰克逊维尔的卜国军博士和大卫霍尔茨曼博士 （圣路易斯华盛顿大学）是apoe领域公认的领导者;每个人都有超过25年的经验 有研究apoE和apoE受体的经验，因为它们与AD和其他衰老的发病机制有关- 相关条件。Bu博士和Holtzman博士有着悠久的合作历史，并有能力分享 在这两个协调机构的U19计划的领导作用。他们也有强有力的领导 分别担任系主任和阿尔茨海默病研究副主任 在各自的机构。Alison Goate博士将担任Icahn的研究中心PI 医学院在西奈山，他们将确保整个U19的整合和协同作用，通过追求 目标1：为U19提供行政结构、财政监督和现场协调 程序.目标2：负责U19活动的质量控制，确保 进行研究，严谨性和研究实践的可重复性，并确保遵守所有 内部和外部监管要求。促进和跟踪开放获取出版物， 向NIH提交进度报告。目标3：促进U19的科学方向和一体化 通过组织内部指导委员会和外部咨询委员会的会议，加强了各组成部分的工作。目的 4：开发和维护apoE网站，作为知识门户，共享资源和数据 平台目标5：为U19研究者以及更广泛的科学家组织年度ApoE研讨会 社区互动和分享研究成果。这些创新目标将确保 U19团队研究人员的严格努力将导致新的发现，为治疗策略提供信息。

PROJECT SUMMARY (APOE U19 Core A: Administrative Core) The Administrative Core will lead this U19 project by providing administrative, fiscal, and scientific oversight and promoting synergy of all Cores and Projects to address the ApoE Cascade Hypothesis. Core A will serve several functions to facilitate the scientific objectives and rigor of this U19. It will also serve the broader scientific community by sharing knowledge, resources, and datasets through a web portal and by promoting collaboration through an annual ApoE Symposium. Core A will cooperate fully with NIA initiatives with a dedicated leadership team and administrative personnel with relevant experience. As the Co-PIs of this U19 project and Co-Leaders of Core A, Drs. Guojun Bu (Mayo Clinic Jacksonville) and David Holtzman (Washington University in St. Louis) are recognized leaders in the apoE field; each has more than 25 years of experience studying apoE and apoE receptors as they relate to the pathogenesis of AD and other aging- related conditions. Drs. Bu and Holtzman have a long history of collaboration and are well positioned to share leadership roles for this U19 program at the two coordinating institutions. They also have strong leadership experience each serving as a Department Chair and an Associate Director of Alzheimer’s Disease Research Center at their respective institution. Together with Dr. Alison Goate, who will serve as the Site-PI at Icahn School of Medicine at Mount Sinai, they will ensure integration and synergy across the U19 by pursuing the following aims: Aim 1: Provide administrative structure, fiscal oversight, and site coordination for the U19 program. Aim 2: Assume responsibility for the quality control of the U19 activities by ensuring responsible conduct of research, rigor, and reproducibility of research practices, and by ensuring compliance with all internal and external regulatory requirements. Promote and track open-access publications and facilitate submission of progress reports to NIH. Aim 3: Promote the scientific direction and integration of the U19 components by organizing meetings of the Internal Steering Committee and External Advisory Committee. Aim 4: Develop and maintain an apoE website what will serve as knowledge portal, and resource and data sharing platform. Aim 5: Organize Annual ApoE Symposium for U19 investigators as well as the broader scientific community to interact and share research findings. These innovative aims will ensure that the robust and rigorous efforts by the U19 team investigators will lead to new discoveries to inform therapeutic strategies.